The first-in-class targeted therapy inhibits telomerase, a cancer-promoting protein active in many cancers. The U.S. Food and Drug Administration (FDA) has approved imetelstat (Rytelo) for patients with low-risk or intermediate-1 risk myelodysplastic syndromes (MDS)...
The CAR T-cell therapy is now approved for some patients with relapsed/refractory mantle cell lymphoma. The U.S. Food and Drug Administration (FDA) has approved lisocabtagene maraleucel (Breyanzi) for the treatment of adult patients with...
The FDA approved the RET inhibitor selpercatinib for children with thyroid cancer and other solid tumors harboring various RET alterations. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to selpercatinib (Retevmo)...
Tarlatamab-dlle is the first t-cell engager that uses the bispecific antibody design for a solid tumor. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tarlatamab-dlle (Imdelltra) to treat patients with...
The CAR T-cell therapy received accelerated approval to treat advanced cases of pretreated follicular lymphoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to lisocabtagene maraleucel (Breyanzi) for the treatment of...
Tisotumab vedotin-tftv is approved to treat certain recurrent or metastatic cervical cancers. The U.S. Food and Drug Administration (FDA) has approved tisotumab vedotin-tftv (Tivdak) for patients with recurrent or metastatic cervical cancer whose disease...
The FDA approved the BRAF inhibitor tovorafenib for pediatric patients with certain Genetic alterations. The U.S. Food and Drug Administration (FDA) has approved tovorafenib (Ojemda) for the treatment of pediatric patients aged 6 months...
The FDA has approved lutetium Lu 177 dotatate for children 12 years or older with some gastroenteropancreatic neuroendocrine tumors. The U.S. Food and Drug Administration (FDA) has approved lutetium Lu 177 dotatate (Lutathera) for...
The FDA has approved nogapendekin alfa inbakicept-pmln, which stimulates immune cells to fight bladder cancer. The U.S. Food and Drug Administration (FDA) has approved nogapendekin alfa inbakicept-pmln (Anktiva) in combination with Bacillus Calmette-Guérin (BCG),...
The FDA has approved the ALK inhibitor alectinib for surgically resectable NSCLC. The U.S. Food and Drug Administration (FDA) has approved alectinib (Alecensa) for use after the surgical removal of a non-small cell lung...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More